As of 2025-05-16, the Intrinsic Value of WuXi Biologics (Cayman) Inc (2269.HK) is 18.48 HKD. This 2269.HK valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 23.85 HKD, the upside of WuXi Biologics (Cayman) Inc is -22.50%.
The range of the Intrinsic Value is 13.33 - 31.57 HKD
Based on its market price of 23.85 HKD and our intrinsic valuation, WuXi Biologics (Cayman) Inc (2269.HK) is overvalued by 22.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 13.33 - 31.57 | 18.48 | -22.5% |
| DCF (Growth 10y) | 28.75 - 72.51 | 41.12 | 72.4% |
| DCF (EBITDA 5y) | 64.96 - 120.20 | 85.98 | 260.5% |
| DCF (EBITDA 10y) | 81.05 - 167.11 | 113.04 | 373.9% |
| Fair Value | 21.90 - 21.90 | 21.90 | -8.17% |
| P/E | 19.66 - 29.47 | 22.22 | -6.8% |
| EV/EBITDA | 22.93 - 38.64 | 28.97 | 21.5% |
| EPV | (1.21) - (2.08) | (1.65) | -106.9% |
| DDM - Stable | 6.73 - 21.56 | 14.15 | -40.7% |
| DDM - Multi | 19.44 - 50.57 | 28.35 | 18.9% |
| Market Cap (mil) | 98,187.35 |
| Beta | 2.01 |
| Outstanding shares (mil) | 4,116.87 |
| Enterprise Value (mil) | 94,598.75 |
| Market risk premium | 5.98% |
| Cost of Equity | 9.88% |
| Cost of Debt | 4.25% |
| WACC | 9.55% |